公开(公告)号：US20060035265A1

公开(公告)日：2006-02-16

申请号：US11242588

申请日：2005-10-03

Applicant: Per-Ake Nygren ,  Mathias Uhlen ,  Olof Nord

Inventor： Per-Ake Nygren ,  Mathias Uhlen ,  Olof Nord

IPC: C40B40/08 ,  C40B40/10

CPC classification number: C12Q1/6811 ,  C12N15/1075

Abstract: The present invention relates to a nucleic acid molecule or a polypeptide that is selected from a method that includes cell-free expression of nucleic acid molecules immobilized on a sold support system. The present invention also relates to a molecular library that has a solid support system having a plurality of nucleic acid molecules immobilized thereon.

Abstract translation: 本发明涉及一种核酸分子或多肽，其选自包含固定在已售出的支持体系上的核酸分子的无细胞表达的方法。 本发明还涉及具有固定有多个核酸分子的固体支持体系的分子文库。

公开(公告)号：US06210891B1

公开(公告)日：2001-04-03

申请号：US09269436

申请日：1999-07-06

Applicant: Pål Nyren ,  Mathias Uhlen ,  Mostafa Ronaghi

Inventor： Pål Nyren ,  Mathias Uhlen ,  Mostafa Ronaghi

IPC: C12Q168

CPC classification number: C12Q1/6869 ,  C12Q2565/518 ,  C12Q2565/301 ,  C12Q2535/101

Abstract: The present invention provides a method of identifying a base at a target position in a single-stranded sample DNA sequence wherein an extension primer, which hybridizes to the sample DNA immediately adjacent to the target position, is provided and the sample DNA and extension primer are subjected to a polymerization reaction in the presence of a deoxynucleotide or dideoxynucleotide, whereby the deoxynucleotide or dideoxynucleotide will only become incorporated and release pyrophosphate if it is complementary to the base in the target position. Release of pyrophosphate is detected enzymatically and pyrophosphate detection enzyme(s) are included in the polymerization step.

Abstract translation: 本发明提供了在单链样品DNA序列中鉴定目标位置的碱基的方法，其中提供了与紧邻目标位置的样品DNA杂交的延伸引物，并且样品DNA和延伸引物为 在脱氧核苷酸或双脱氧核苷酸的存在下进行聚合反应，由此脱氧核苷酸或双脱氧核苷酸仅在靶位置与碱基互补时才被引入并释放焦磷酸盐。 检测到焦磷酸盐的释放，聚合步骤中包括焦磷酸盐检测酶。

公开(公告)号：US5411732A

公开(公告)日：1995-05-02

申请号：US130430

申请日：1993-10-01

Applicant: Bjorn Lowenadler ,  Erik Holmgren ,  Mathias Uhlen ,  Bjorn Nilsson

Inventor： Bjorn Lowenadler ,  Erik Holmgren ,  Mathias Uhlen ,  Bjorn Nilsson

IPC: C07K14/575 ,  A61K39/00 ,  C07K14/00 ,  C07K14/195 ,  C07K14/31 ,  C07K14/41 ,  C07K14/65 ,  C07K16/00 ,  C07K16/44 ,  C07K19/00 ,  C12N15/00 ,  C12N15/09 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  G01N33/531 ,  G01N33/577

CPC classification number: A61K39/00 ,  A61K39/0005 ,  C07K14/31 ,  C07K14/65 ,  C07K16/44 ,  A61K2039/6068

Abstract: A process for preparing antibodies specific for an amino acid sequence which comprises immunizing a mammal with a fused protein comprising said amino acid sequence fused to an immunogenic IgG binding protein is disclosed.

Abstract translation: 公开了一种制备对氨基酸序列特异性的抗体的方法，其包括用包含与免疫原性IgG结合蛋白融合的所述氨基酸序列的融合蛋白免疫哺乳动物。

公开(公告)号：US20120269764A1

公开(公告)日：2012-10-25

申请号：US13201742

申请日：2009-12-17

Applicant: Mathias Uhlen ,  Fredrik Ponten ,  Karin Jirstrom

Inventor： Mathias Uhlen ,  Fredrik Ponten ,  Karin Jirstrom

IPC: G01N33/574 ,  G01N21/64 ,  C07H21/04 ,  C07K14/47 ,  C07K7/06 ,  C07K16/18 ,  G01N21/76 ,  A61K38/20

CPC classification number: G01N33/689 ,  C07K14/4748 ,  G01N33/5743

Abstract: A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Abstract translation: 一种用于确定具有恶性黑素瘤的哺乳动物受试者是否属于第一组或第二组的方法，其中提供了第一组受试者的预后优于第二组受试者的预后。 该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白的量，并确定与评估量对应的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

公开(公告)号：US20120034218A1

公开(公告)日：2012-02-09

申请号：US13210816

申请日：2011-08-16

Applicant: Mathias Uhlen ,  Fredrik Pontén ,  Karin Jirström

Inventor： Mathias Uhlen ,  Fredrik Pontén ,  Karin Jirström

IPC: A61K39/395 ,  C12Q1/68 ,  C07K7/06 ,  A61K31/7068 ,  A61P35/00 ,  C07K14/47 ,  C40B30/04 ,  G01N33/566

CPC classification number: C07K16/18 ,  A61K31/7068 ,  A61K39/39533 ,  A61K45/06 ,  C07K14/4748 ,  C07K16/3038 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57419 ,  A61K2300/00

Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Abstract translation: 本发明提供了用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，例如方法，其中第一组受试者的预后优于第二组受试者的预后 。 该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白或RBM3 mRNA分子的量，并确定对应于评估量的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

公开(公告)号：US20050100970A1

公开(公告)日：2005-05-12

申请号：US11000747

申请日：2004-12-01

Applicant: Mathias Uhlen ,  Sophia Hober

Inventor： Mathias Uhlen ,  Sophia Hober

IPC: B01J20/281 ,  B01D15/08 ,  B01J20/24 ,  C07K1/22 ,  C07K14/00 ,  C07K14/31 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/01 ,  C12N15/09 ,  C12N15/10 ,  C40B40/02 ,  G01N30/88 ,  G01N33/53 ,  G01N33/543

CPC classification number: C07K14/31 ,  C07K1/047 ,  C07K1/22 ,  C07K2319/00 ,  C12N15/1037 ,  C40B40/02

Abstract: Methods of affinity separation wherein the affinity ligand is immobilized proteinaceous ligand wherein one or more of its asparagine (Asn) residues has been modified. Methods of making a stabilized combinatorial protein by a) modification of Asn residues within a protein molecule to increase stability of the protein in alkaline conditions, and b) randomization of the protein molecule to modify its binding characteristics, and combinatorial proteins wherein in a step separate from the randomization step, the stability of the protein in alkaline conditions has been increased by modifying one or more of its Asn residues.

Abstract translation: 亲和力分离方法，其中亲和配体是固定化的蛋白质配体，其中一个或多个其天冬酰胺（Asn）残基已被修饰。 通过以下方式制备稳定的组合蛋白的方法：a）修饰蛋白质分子中的Asn残基以增加蛋白质在碱性条件下的稳定性，以及b）蛋白质分子的随机化以修饰其结合特征，以及组合蛋白，其中分离步骤 通过随机化步骤，通过修饰其一种或多种Asn残基来增加蛋白质在碱性条件下的稳定性。

公开(公告)号：US06558924B1

公开(公告)日：2003-05-06

申请号：US09485286

申请日：2000-02-07

Applicant: Stefan Stahl ,  Mathias Uhlen ,  Per-Ake Nygren ,  Per Jonasson

Inventor： Stefan Stahl ,  Mathias Uhlen ,  Per-Ake Nygren ,  Per Jonasson

IPC: C12N1500

CPC classification number: C12N15/62 ,  C07K14/62 ,  C07K2319/00 ,  C07K2319/50 ,  C07K2319/705 ,  C07K2319/75

Abstract: The present invention provides a method of producing an insulin C-peptide, which comprises expressing in a host cell a multimeric polypeptide comprising multiple copies of the insulin C-peptide, and cleaving the expressed polypeptide to release single copies of the insulin C-peptide. Also provided are nucleic acid molecules, expression vectors and host cells, for use in such a method and the multimeric insulin C-peptide polypeptide expressed and cleaved in such a method.

Abstract translation: 本发明提供了一种生产胰岛素C肽的方法，其包括在宿主细胞中表达包含胰岛素C-肽的多个拷贝的多聚体多肽，并切割表达的多肽以释放胰岛素C肽的单拷贝。 还提供了用于这种方法的核酸分子，表达载体和宿主细胞，并且以这种方法表达和切割多聚胰岛素C肽多肽。

公开(公告)号：US5958736A

公开(公告)日：1999-09-28

申请号：US629039

申请日：1996-04-08

Applicant: Stefan St.ang.hl ,  Per-.ANG.ke Nygren ,  Marianne Hansson ,  Mathias Uhlen ,  Thien Ngoc Nguyen

Inventor： Stefan St.ang.hl ,  Per-.ANG.ke Nygren ,  Marianne Hansson ,  Mathias Uhlen ,  Thien Ngoc Nguyen

IPC: G01N33/569 ,  A61K38/00 ,  A61K39/00 ,  C07K14/135 ,  C07K14/31 ,  C07K14/315 ,  C07K14/445 ,  C07K16/40 ,  C12N1/21 ,  C12N15/09 ,  C12N15/62 ,  C12N15/74 ,  C12R1/19 ,  C12N15/00

CPC classification number: C07K14/005 ,  C07K14/31 ,  C07K14/315 ,  C07K14/445 ,  C07K16/40 ,  C12N15/62 ,  C12N15/74 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/705 ,  C12N2760/18522 ,  Y10S435/882 ,  Y10S435/883

Abstract: Tripartite recombinant DNA encoding fusion proteins which comprise three sequences, i.e., a signal peptide which is operable in a Gram positive bacterium, an immunogenic polypeptide linked thereto which is not normally expressed in a Gram positive bacterium, and a cell wall spanning and a membrane anchoring sequence, as well as their use in Gram positive bacteria to express the resultant fusion protein on their surface are described. The preferred cell wall spanning and anchoring polypeptides include Staphylococcus protein A and Streptococcus protein G.

Abstract translation: 编码融合蛋白的三重重组DNA，其包含三个序列，即可在革兰氏阳性细菌中可操作的信号肽，与之相连的免疫原性多肽，其通常不在革兰氏阳性细菌中表达，细胞壁跨越和膜锚定 描述了它们在革兰氏阳性细菌中在其表面上表达所得融合蛋白的用途。 跨越和锚定多肽的优选细胞壁包括葡萄球菌蛋白A和链球菌蛋白G.

公开(公告)号：US5534424A

公开(公告)日：1996-07-09

申请号：US331552

申请日：1995-04-18

Applicant: Mathias Uhlen ,  Joakim Lundeberg

Inventor： Mathias Uhlen ,  Joakim Lundeberg

IPC: C12N15/09 ,  C12Q1/68 ,  C12P19/34 ,  C07H21/04 ,  C12Q1/70

CPC classification number: C12Q1/6858 ,  C12Q1/6834 ,  C12Q1/6869

Abstract: The invention provides a method of identification of the base in a target position in a DNA sequence wherein sample DNA is subjected to amplification; the amplified DNA is immobilised and then subjected to strand separation, the non-immobilised strand being removed and an extension primer, which hybridises to the immobilised DNA immediately adjacent to the target position, is provided; each of four aliquots of the immobilised single stranded DNA is then subjected to a polymerase reaction in the presence of a dideoxynucleotide, each aliquot using a different dideoxynucleotide whereby only the dideoxynucleotide whereby only the dideoxynucleotide complementary to the base in the target position becomes incorpored; the four aliquots are then subjected to extension in the presence of all four deoxynucleotides, whereby in each aliquot the DNA which has not reacted with the dideoxynucleotide is extended to form double stranded DNA while the dideoxy-blocked DNA remains as non-extended DNA; followed by identification of the double stranded and/or non-extended DNA to indicate which dideoxynucleotide was incorporated and hence which base was present in the target position.

Abstract translation: PCT No.PCT / EP93 / 01203 371日期1995年04月18日 102（e）日期1995年4月18日PCT提交1993年5月12日PCT公布。 公开号WO93 / 23562 日期：1993年11月25日。本发明提供了在DNA序列中的靶位置鉴定碱基的方法，其中对样品DNA进行扩增; 将扩增的DNA固定化，然后进行链分离，除去非固定化链和延伸引物，其与紧邻目标位置的固定化DNA杂交; 然后在双脱氧核苷酸存在的情况下，将四个等分的固定化单链DNA中的每一个进行聚合酶反应，每个等分试样使用不同的双脱氧核苷酸，从而只有双脱氧核苷酸，其中只有与目标位置的碱基互补的双脱氧核苷酸才会被吸收; 然后在四种脱氧核苷酸的存在下将四个等分试样延伸，由此在每个等分试样中，未与双脱氧核苷酸反应的DNA延伸形成双链DNA，而双脱氧封闭的DNA保留为非延伸的DNA; 随后鉴定双链和/或未延伸的DNA以指示哪个双脱氧核苷酸被引入，因此哪个碱基存在于目标位置。

公开(公告)号：US20110142828A1

公开(公告)日：2011-06-16

申请号：US12946934

申请日：2010-11-16

Applicant: Mathias UHLEN ,  Fredrik PONTEN ,  Karin JIRSTRÕM ,  Donal J. Brennan

Inventor： Mathias UHLEN ,  Fredrik PONTEN ,  Karin JIRSTRÕM ,  Donal J. Brennan

IPC: A61K39/395 ,  C12Q1/26 ,  C12Q1/68 ,  G01N33/68 ,  C40B30/00 ,  A61K31/138 ,  A61K31/4535 ,  A61P35/00

CPC classification number: G01N33/57415 ,  C12Q1/26 ,  G01N33/573 ,  G01N2333/90209

Abstract: The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value obtained in step b) with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. Further, a corresponding method of treatment is provided as well as further methods uses and means which may be employed in connection with breast cancer treatment or treatment prediction.

Abstract translation: 本发明提供了一种用于确定具有乳腺癌的哺乳动物受试者是否可能受益于内分泌治疗的方法，包括以下步骤：提供从所述受试者获得的早期样品; 评估存在于所述样品的至少一部分中的HMGCR蛋白或HMGCR mRNA的量，并确定对应于所述量的样品值; 将步骤b）中获得的样本值与参考值进行比较; 并且如果所述样品值高于所述参考值，则认为受试者可能受益于内分泌治疗。 此外，提供相应的治疗方法以及可用于与乳腺癌治疗或治疗预测有关的其它方法用途和手段。